Authors: BECK WT GROGAN TM WILLMAN CL CORDONCARDO C PARHAM DM KUTTESCH JF ANDREEFF M BATES SE BERARD CW BOYETT JM BROPHY NA BROXTERMAN HJ CHAN HSL DALTON WS DIETEL M FOJO AT GASCOYNE RD HEAD D HOUGHTON PJ SRIVASTAVA DK LEHNERT M LEITH CP PAIETTA E PAVELIC ZP RIMSZA L RONINSON IB SIKIC BI TWENTYMAN PR WARNKE R WEINSTEIN R

Citation: Wt. Beck et al., METHODS TO DETECT P-GLYCOPROTEIN-ASSOCIATED MULTIDRUG-RESISTANCE IN PATIENTS TUMORS - CONSENSUS RECOMMENDATIONS, Cancer research, 56(13), 1996, pp. 3010-3020

Authors: LUM BL FISHER GA HAUSDORF J GOTTWALD M COLLINS H BROPHY NA EHSAN MN HALSEY J SIKIC BI

Citation: Bl. Lum et al., THE EFFECT OF SDZ-PSC-833, A CYCLOSPORINE-D ANALOG, ON THE PHARMACOKINETIC BEHAVIOR OF ETOPOSIDE (E) DURING A PHASE-I TRIAL TO MODULATE MULTIDRUG-RESISTANCE, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 175-175

Authors: BROPHY NA MARIE JP ROJAS VA WARNKE RA MCFALL PJ SMITH SD SIKIC BI

Citation: Na. Brophy et al., MDR1 GENE-EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIAS AND LYMPHOMAS - A CRITICAL-EVALUATION BY 4 TECHNIQUES, Leukemia, 8(2), 1994, pp. 327-335

Authors: BARTLETT NL LUM BL FISHER GA BROPHY NA EHSAN MN HALSEY J SIKIC BI

Citation: Nl. Bartlett et al., PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE, Journal of clinical oncology, 12(4), 1994, pp. 835-842

Authors: LUM BL BARTLETT NL FISHER GA BROPHY NA EHSAN M HALSEY J SIKIC BI

Citation: Bl. Lum et al., PHARMACODYNAMICS (PD) OF DOXORUBICIN (DOX) WITH CYCLOSPORINE (CSA) ASA MODULATOR OF DRUG-RESISTANCE, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 210-210

Authors: LUM BL FISHER GA BROPHY NA YAHANDA AM ADLER KM KAUBISCH S HALSEY J SIKIC BI

Citation: Bl. Lum et al., CLINICAL-TRIALS OF MODULATION OF MULTIDRUG-RESISTANCE - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS, Cancer, 72(11), 1993, pp. 3502-3514